✨ Free AI Report
Lexicon Pharmaceuticals, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Lexicon Pharmaceuticals, Inc.
Company Research

Lexicon Pharmaceuticals, Inc.: Business Overview, Financials & Competitive Analysis

Lexicon Pharmaceuticals, Inc. scores 6/10 on the AskCyborg Cyborg Score (Solid). Risk-reward turnaround play dependent on successful Phase 3 completion and regulatory approvals for pilavapadin and sotagliflozin in target indications. Strong pipeline advancement with multiple late-stage assets and recent partnership milestones, but challenged by deep losses ($200M+ annually), minimal profitability, and early revenue stage. Recent 248x revenue growth shows promise.

What is Lexicon Pharmaceuticals, Inc.'s industry? Lexicon Pharmaceuticals, Inc. (lexpharma.com) operates in Biopharmaceutical / Pharmaceutical Development. AskCyborg classifies Lexicon Pharmaceuticals, Inc. under Biopharmaceutical / Pharmaceutical Development in its company registry.

Lexicon Pharmaceuticals is a biopharmaceutical company focused on discovering and commercializing precision medicines using Nobel Prize-winning gene science technology. The company is advancing a pipeline of late-stag...

6/ 10Solid

Cyborg Score thesis

Risk-reward turnaround play dependent on successful Phase 3 completion and regulatory approvals for pilavapadin and sotagliflozin...

Read the full analyst-debate transcript →
Industry Biopharmaceutical / Pharmaceutical Development
3 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Lexicon Pharmaceuticals, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Lexicon Pharmaceuticals, Inc.

AskCyborg analysts argue the bull and bear cases for Lexicon Pharmaceuticals, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Lexicon Pharmaceuticals, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Lexicon Pharmaceuticals, Inc. Overview

Pro stress-test →

Lexicon Pharmaceuticals is a biopharmaceutical company focused on discovering and commercializing precision medicines using Nobel Prize-winning gene science technology. The company is advancing a pipeline of late-stage cardiometabolic and neuroscience therapies, including INPEFA (commercialized), pilavapadin, LX9851, and sotagliflozin, with significant revenue growth achieved in 2024.

Strategic Profile

Pro stress-test →

Lexicon leverages proprietary gene science platforms to develop targeted therapeutics in high-demand markets including heart failure, type 2 diabetes, chronic kidney disease, and obesity. Strategic partnerships with Novo Nordisk, Viatris, and Bristol-Myers Squibb provide commercialization capabilities and capital support, positioning the company as a potential turnaround story despite historical challenges.

Competitive Landscape

Pro stress-test →

Lexicon competes in crowded cardiometabolic and neuroscience markets against established pharma and well-funded biotech. Key competitors include Sangamo Therapeutics, Apellis Pharmaceuticals, Iovance Biotherapeutics, and others developing similar indications. Differentiation through proprietary gene science and strategic partnerships with larger pharma (Novo Nordisk, Bristol-Myers Squibb) provides distribution and credibility advantages.

Industry Context

Lexicon Pharmaceuticals, Inc. operates in Biopharmaceutical / Pharmaceutical Development.

Key facts

Founded: 1995 · Headquarters: The Woodlands, Texas, USA · Revenue: $31.08M (2024)

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Lexicon Pharmaceuticals, Inc..

  • Revenue surged 2481% to $31.08M in 2024, driven by INPEFA commercialization and partnerships, signaling successful transition from development-stage company
  • Three late-stage assets with high-reward potential: pilavapadin (neuropathic pain, obesity), sotagliflozin (heart failure, type 1 diabetes, HCM), and LX9851 (partnered with Novo Nordisk for obesity indication)
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • February 2026Lexicon announced closing of underwritten public offering for capital raise
  • January 2026Presented at J.P. Morgan Healthcare Conference; SONATA-HCM enrollment on track for 2026 completion; $10M milestone payment from Novo Nordisk
  • +2 moreTrack every material event for Lexicon Pharmaceuticals, Inc. as it happens. Explore monitoring →
Get alerted when Lexicon Pharmaceuticals, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

SGLT2 Inhibitors & GLP-1 AgonistsEstablished therapies in cardio-metabolic space→Gene Therapy PlatformsCompeting precision medicine approaches→Rare Disease TherapeuticsLate-stage biotech competitors in specialized indications→

Compare Lexicon Pharmaceuticals, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Lexicon Pharmaceuticals, Inc. operates in Biopharmaceutical / Pharmaceutical Development. See how the rest of the sector scores on the Cyborg framework.

Top companies in Biopharmaceutical by Cyborg Score

Browse Biopharmaceutical / Pharmaceutical Development research →
NEW · MCP server

Ask your AI assistant about Lexicon Pharmaceuticals, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Lexicon Pharmaceuticals, Inc. and its top competitor on Cyborg Score”
“What did Lexicon Pharmaceuticals, Inc. do this quarter?”
“Is Lexicon Pharmaceuticals, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does Lexicon Pharmaceuticals, Inc. do?+
Lexicon Pharmaceuticals is a biopharmaceutical company focused on discovering and commercializing precision medicines using Nobel Prize-winning gene science technology. The company is advancing a pipeline of late-stag...
What is Lexicon Pharmaceuticals, Inc.'s Cyborg Score?+
Lexicon Pharmaceuticals, Inc. has a Cyborg Score of 6/10 (Solid). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Lexicon Pharmaceuticals, Inc.'s main competitors?+
Named competitors include SGLT2 Inhibitors & GLP-1 Agonists, Gene Therapy Platforms, Rare Disease Therapeutics. The full competitive landscape is in the AskCyborg report.
How can I get the full Lexicon Pharmaceuticals, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Lexicon Pharmaceuticals, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Lexicon Pharmaceuticals, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biopharmaceutical research

Companies in the same sector and named competitors, ranked by Cyborg Score.

9Eli Lilly and Company8argenx SE8Ascendis Pharma A/S8Avidity Biosciences, Inc.8BeOne Medicines AG8Celltrion, Inc.8Corcept Therapeutics Incorporated8Insmed Incorporated8Roivant Sciences Ltd.8Terns Pharmaceuticals, Inc.Top companies in Biopharmaceutical by Cyborg Score